آخرین یافته‌های کروناویروس: پاتوژنز و درمان آن

نوع مقاله : مقاله مروری

نویسندگان

1 استادیار، بخش واکسن‌های ویروسی انسانی، مؤسسه‌ی سرم و واکسن‌سازی رازی کرج، کرج، ایران

2 گروه ایمنی‌شناسی، دانشکده‌ی پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران

3 دانشیار، گروه ایمنی‌شناسی، دانشکده‌ی پزشکی و مرکز تحقیقات فیزیولوژی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران

چکیده

بیماری ویروس کرونا (Coronavirus diseases-2019 یا COVID-19) یک نوع پنومونی حاد ویروسی است که با شیوع ناگهانی ازشهر ووهان چین شروع شده است. این بیماری، اگر چه شباهت زیادی با سندرم شدید حاد تنفسی (Severe acute respiratory syndrome یا SARS) و سندرم تنفسی خاور میانه (Middle East respiratory syndrome یا MERS) دارد، اما سرعت سرایت بیش از حد این بیماری، آن را از سایر بیماری‌های پنومونی ویروسی متمایز کرده است. عوارض ریوی و عفونت‌های ناشی از این ویروس و نبود درمان‌های اختصاصی، توانسته است یکی از بغرنج‌ترین همه‌گیری‌های قرن اخیر را به وجود آورد. در این مقاله‌ی مروری سعی شده است که آخرین یافته‌های ایمنوپاتوژنز و درمان‌های کاربردی و جدید ویروس کرونا به بحث و تبادل نظر گذاشته شود.

کلیدواژه‌ها

عنوان مقاله [English]

Recent Findings of Coronavirus: The Pathogenesis and Treatment

نویسندگان [English]

  • Reza Bastan 1
  • Neda Kasiri 2
  • Nahid Eskandari 3
1 Assistant Professor, Department of Human Vaccines, Razi Serum and Vaccine Research Institute, Karaj, Iran
2 Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 Associate Professor, Department of Immunology, School of Medicine AND Applied Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
چکیده [English]

Coronavirus disease-2019 (COVID-19) is a type of acute viral pneumonia, which began with a sudden outbreak in Wuhan, China. Although closely related to severe acute respiratory syndrome, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), the disease excessive transmission rate distinguishes it from other viral pneumonia diseases. The pulmonary complications and infections caused by this virus, as well as the lack of specific therapeutic have caused one of the most complicated epidemics of the last century. In this review article, we attempted to discuss and describe the latest findings of immunopathogenesis, as well new and applicable treatments for coronavirus disease.

کلیدواژه‌ها [English]

  • Coronavirus infections
  • Pneumonia
  • MERS virus
  • SARS virus

مراجع

  1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270-3.
  2. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: Recent insights into emerging coronaviruses. Nat Rev Microbiol 2016; 14(8): 523-34.
  3. Johnson ER, Matthay MA. Acute lung injury: Epidemiology, pathogenesis, and treatment. J Aerosol Med Pulm Drug Deliv 2010; 23(4): 243-52.
  4. Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 2016; 24(6): 490-502.
  5. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395(10224): 565-74.
  6. Fehr AR, Perlman S. Coronaviruses: An overview of their replication and pathogenesis. Methods Mol Biol 2015; 1282: 1-23.
  7. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426(6965): 450-4.
  8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
  9. Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nat Med 2004; 10(12 Suppl): S88-S97.
  10. Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495(7440): 251-4.
  11. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020; 579(7798): 265-9.
  12. Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achenbach JE, Babcock GJ, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci USA 2004; 101(44): 15748-53.
  13. Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci USA 2009; 106(14): 5871-6.
  14. Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 2009; 7(6): 439-50.
  15. Keicho N, Itoyama S, Kashiwase K, Phi NC, Long HT, Ha LD, et al. Association of human leukocyte antigen class II alleles with severe acute respiratory syndrome in the Vietnamese population. Hum Immunol 2009; 70(7): 527-31.
  16. Chen YM, Liang SY, Shih YP, Chen CY, Lee YM, Chang L, et al. Epidemiological and genetic correlates of severe acute respiratory syndrome coronavirus infection in the hospital with the highest nosocomial infection rate in Taiwan in 2003. J Clin Microbiol 2006; 44(2): 359-65.
  17. Wang SF, Chen KH, Chen M, Li WY, Chen YJ, Tsao CH, et al. Human-leukocyte antigen class I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection. Viral Immunol 2011; 24(5): 421-6.
  18. Hajeer AH, Balkhy H, Johani S, Yousef MZ, Arabi Y. Association of human leukocyte antigen class II alleles with severe Middle East respiratory syndrome-coronavirus infection. Ann Thorac Med 2016; 11(3): 211-3.
  19. Tu X, Chong WP, Zhai Y, Zhang H, Zhang F, Wang S, et al. Functional polymorphisms of the CCL2 and MBL genes cumulatively increase susceptibility to severe acute respiratory syndrome coronavirus infection. J Infect 2015; 71(1): 101-9.
  20. Li G, Chen X, Xu A. Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med 2003; 349(5): 508-9.
  21. Fan YY, Huang ZT, Li L, Wu MH, Yu T, Koup RA, et al. Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection. Arch Virol 2009; 154(7): 1093-9.
  22. Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fett C, Zhao J, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA 2014; 111(13): 4970-5.
  23. Williams AE, Chambers RC. The mercurial nature of neutrophils: still an enigma in ARDS? Am J Physiol Lung Cell Mol Physiol 2014; 306(3): L217-L230.
  24. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017; 39(5): 529-39.
  25. Cameron MJ, Bermejo-Martin JF, Danesh A, Muller MP, Kelvin DJ. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res 2008; 133(1): 13-9.
  26. Channappanavar R, Fehr AR, Zheng J, Wohlford-Lenane C, Abrahante JE, Mack M, et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest 2019; 130: 3625-39.
  27. Niemeyer D, Zillinger T, Muth D, Zielecki F, Horvath G, Suliman T, et al. Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. J Virol 2013; 87(22): 12489-95.
  28. Menachery VD, Schafer A, Burnum-Johnson KE, Mitchell HD, Eisfeld AJ, Walters KB, et al. MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape. Proc Natl Acad Sci USA 2018; 115(5): E1012-E1021.
  29. van DN, Schafer A, Menachery VD, Letko M, Bushmaker T, Fischer RJ, et al. SARS-Like Coronavirus WIV1-CoV Does Not Replicate in Egyptian Fruit Bats (Rousettus aegyptiacus). Viruses 2018; 10(12).
  30. Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, et al. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. Clin Chem 2020; 66(4): 549-55.
  31. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020; 25(3). [Epub ahead of print].
  32. To KK, Tsang OT, Chik-Yan YC, Chan KH, Wu TC, Chan JMC, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis 2020.
  33. Yam WC, Chan KH, Poon LL, Guan Y, Yuen KY, Seto WH, et al. Evaluation of reverse transcription-PCR assays for rapid diagnosis of severe acute respiratory syndrome associated with a novel coronavirus. J Clin Microbiol 2003; 41(10): 4521-4.
  34. Poon LL, Chan KH, Wong OK, Yam WC, Yuen KY, Guan Y, et al. Early diagnosis of SARS coronavirus infection by real time RT-PCR. J Clin Virol 2003; 28(3): 233-8.
  35. Chan KH, Chan JF, Tse H, Chen H, Lau CC, Cai JP, et al. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J Infect 2013; 67(2): 130-40.
  36. Momattin H, Al-Ali AY, Al-Tawfiq JA. A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Travel Med Infect Dis 2019; 30: 9-18.
  37. Pruijssers AJ, Denison MR. Nucleoside analogues for the treatment of coronavirus infections. Curr Opin Virol 2019; 35: 57-62.
  38. Sarma P, Prajapat M, Avti P, Kaur H, Kumar S, Medhi B. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach. Indian J Pharmacol 2020; 52(1): 1-5.
  39. Zhang T, He Y, Xu W, Ma A, Yang Y, Xu KF. Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need. Sci China Life Sci 2020; 63(5): 774-6.
  40. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9(396).
  41. Mulangu S, Dodd LE, Davey RT, Tshiani MO, Proschan M, Mukadi D, et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med 2019; 381(24): 2293-303.
  42. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016; 531(7594): 381-5.
  43. Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11(1): 222.
  44. Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol 2020.
  45. Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF, et al. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 2014; 95(Pt 3): 571-7.
  46. Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013; 67(6): 606-16.
  47. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis. J Infect Dis 2015; 211(1): 80-90.
  48. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727-33.
  49. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14(1): 72-3.
مجله دانشکده پزشکی اصفهان
دوره 38، شماره 567 - شماره پیاپی 567
فروردین و اردیبهشت 1399
صفحه 154-164

فایل ها

سابقه مقاله

  • تاریخ دریافت: 11 فروردین 1399
  • تاریخ بازنگری: 08 اردیبهشت 1403
  • تاریخ پذیرش: 17 فروردین 1401

هم رسانی

ارجاع به این مقاله

آمار